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Abstract Continuous subcutaneous glucose monitoring
(CGM) is a developing technology in the treatment of
diabetes mellitus. The first randomised controlled trials on
its efficacy have been performed. In several studies, CGM
lowered HbA1c in adult patients with suboptimally con-
trolled type 1 diabetes mellitus, when selecting compliant
patients who tolerate the device. However, as a preventive
tool for hypoglycaemia, CGM has not fulfilled the great
expectations. Increasing reimbursement of CGM is expected
in the near future, awaiting studies on cost-effectiveness.
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RCT Randomised controlled trial
SMBG Self-monitoring of blood glucose
Pioneering work of artificially replacing the glucose-
monitoring function of the pancreas started in the 1970s
[1]. With the introduction of the microdialysis technique in
the early 1990s, the future of continuous subcutaneous
glucose monitoring (CGM) seemed bright and shiny [2, 3].
The great expectation was that, by providing the patient
with a continuous stream of data and alarms for otherwise
unrecognised (nocturnal) hypo- and hyperglycaemia, the
HbA1c target of <7% was in reach and the main barrier to
effective diabetes treatment—t h eo c c u r r e n c eo fs e v e r e
hypoglycaemia—could be overcome [4–6]. Even more,
integrating CGM and continuous subcutaneous insulin
infusion (CSII) would mean it would be a matter of time
before the closed-loop system would be available [7].
Several years later, the first needle-type sensor became
clinically available, though it could only be read out retro-
spectively [8]. Currently, there are three real-time CGM
systems on the market that are approved by the US Food
and Drug Administration (FDA) and have the Conformité
Européenne (CE) mark: the Freestyle Navigator (Abbott
Diabetes Care, Alameda, CA, USA); the Guardian Real-
Time (Medtronic MiniMed, Northridge, CA, USA); and the
DexCom SEVEN (DexCom, San Diego, CA, USA; only
available in the USA). All these systems measure glucose
in the subcutaneous tissue and provide real-time glucose
measurements every 1–5 min. The first randomised
controlled trials (RCTs) have now been performed with
real-time CGM, prompting the next questions: did the
sensor fulfil expectations and is this reflected in the current
reimbursement status of the device?
Effect on HbA1c
The first RCT, performed by Deiss and colleagues,
investigated a needle-type continuous subcutaneous glucose
monitor in patients with poorly controlled type 1 diabetes
(HbA1c ≥8.1% on intensive treatment) [9]. There was a
difference in HbA1c reduction of 0.6% after 3 months in
favour of patients who were instructed to use the device
continuously, as compared with patients using conventional
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this did not result in a significant HbA1c improvement. A
subsequent 26 week randomised treat-to-target study
performed by Hirsch and coworkers (the STAR 1 trial)
yielded disappointing results [10]. There was no significant
difference in change in HbA1c between type 1 diabetes
patients using CSII randomised to either augmenting their
current therapy with CGM or continuing with their standard
self-monitoring of blood glucose (SMBG). In both groups,
there was a decrease in HbA1c of 0.6–0.7%. That the
decreases in HbA1c were comparable in both groups was
attributed to intensification of the treatment in both the
control and intervention groups. It seems that in an attempt
to assure equal attention times in both groups, the control
group was treated more intensively than would be feasible
in daily practice. In the Juvenile Diabetes Research
Foundation (JDRF) study, three different age groups (≥25,
15–24 and 8–14 years) were randomised to either CGM or
SMBG continuation [11]. All patients had type 1 diabetes
and the vast majority were already using CSII. The mean
difference in HbA1c change was 0.5% after 26 weeks in
favour of patients using CGM, but this was only in those
aged 25 years and older. No significant difference in HbA1c
change was detected in the other age groups. In both the
STAR 1 and the JDRF trials, the frequency of sensor usage
was strongly correlated to the decrease in HbA1c. This is in
line with the study from Deiss et al. [9] and the recently
published RealTrend study [12]. In this latter study, patients
administering multiple daily injections and with an HbA1c≥
8% at inclusion started with either CSII therapy or sensor-
augmented pump therapy for 26 weeks. From a predefined
analysis, HbA1c improved compared with the CSII group
only in patients using the sensor >70% of the time.
Unfortunately, patients in the sensor-augmented pump
group had already used CGM for 9 days before the baseline
HbA1c measurement was performed and therefore the
observed HbA1c difference, 0.41%, may have been under-
estimated. The combination of CGM and CSII has also
been investigated in the recently presented Eurythmics trial,
where a difference in HbA1c improvement of 1.21% in
favour of the sensor-augmented pump group was found
when type 1 diabetes patients (HbA1c at entry ≥8.2%), who
were using multiple daily injection therapy and SMBG,
were randomised to continuing their current therapy or
starting CGM-augmented insulin-pump therapy [13]. It is
interesting that the JDRF trial and the Eurythmics trial, both
showing a significant HbA1c improvement in the interven-
tion group, confronted patients with a short period of
blinded CGM usage at baseline before randomisation.
Patients who did not tolerate the device, and therefore
would be likely to drop out or be non-compliant during the
study course, were at least partly filtered out before
randomisation.
Effect on severe hypoglycaemia
The improvement in HbA1c in the different RCTs was not
accompanied by a significant increase in severe hypogly-
caemia [9–13]. This seems reassuring, but CGM did not
fulfil the expectation that its use would reduce the frequency
of severe hypoglycaemic events [14]. Even more, in the
STAR 1 trial, the use of CGM was associated with a
significant increase in severe hypoglycaemia. This is most
likely related to the reduced awareness of auditory and
vibratory alarms during hypoglycaemia and non-use of the
device during high-risk activities, such as intensive sports.
No study so far has shown a decrease in the frequency of
severe hypoglycaemia in a CGM arm as compared with the
control arm in type 1 diabetes. Indeed, sensors have an
inaccuracy of up to 21% when comparing plasma glucose
values with subcutaneous glucose values [15]. This inaccu-
racy is even more pronounced in the hypoglycaemic range.
In addition, the usefulness of the CGM devices for detecting
forthcoming hypoglycaemia is limited by a putative physi-
ological delay between the blood glucose and glucose
concentration in the subcutaneous tissue, which is accompa-
nied by an instrumental delay of the sensor [16]. In other
words, patients need more time to prevent hypoglycaemia,
especially when they have hypoglycaemia unawareness.
Perhaps the developing technology will result in an alarm
function for predicting hypoglycaemia by using the rate of
change in glucose in the lower euglycaemic range. For
now, CGM is insufficient for the prevention of severe
hypoglycaemia.
Costs and reimbursement
Interestingly, it is the argument of possibly preventing severe
hypoglycaemiathathaspersuadedhealthcareorganisationsin
Israel to reimburse CGM use. Children with type 1 diabetes
who have experienced more than two severe hypoglycaemic
episodes within 1 year are entitled to CGM compensation. In
addition, real-time CGM is now covered by the majority of
health plans in the USA, including the federal Medicare
program. Reimbursement is generally available for type 1
patients with severe hypoglycaemia or those who are not
meeting American Diabetes Association HbA1c targets. In
the Netherlands and part of Italy, retrospective CGM is
currently reimbursed. The Czech Republic covers up to four
sensors per year for retrospective CGM and in Sweden, real-
time CGM is reimbursed for patients using CSII and having
two or more severe hypoglycaemic episodes per year,
children who require at least ten plasma glucose tests per
24 h and patients with HbA1c >10% while receiving
optimised insulin therapy. The reimbursement indication of
hypoglycaemia illustrates that so far, coverage was based on
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that CGM is not able to reduce severe hypoglycaemia, but
we need randomised trials in patients at high risk for severe
hypoglycaemia (i.e. those suffering from hypoglycaemia
unawareness). From the results of the clinical trials to date,
we can now argue that CGM offers a clear health benefit,
expressed as HbA1c lowering, for type 1 diabetes patients
with HbA1c values above 8%. The additional costs for
sensors are US$4380 per person year compared with US
$550–2740 when using SMBG [17]. Consequently, we need
to calculate whether the long-term health benefits of CGM
following from ascertained lowering of HbA1c outweigh the
costs when compared with standard care with multiple daily
injections and/or insulin pumps. A similar comparison was
performed by Roze and colleagues indicating that the cost-
effectiveness of CSII is acceptable [18]. A technical
appraisal from the National Institute for Health and Clinical
Excellence (England and Wales) seems timely.
Other patient groups
The application of CGM in patient groups other than those
with type 1 diabetes is limited. No trials with adequate
duration assessing HbA1c change have been performed for
patients with type 2 diabetes [19]. One particular patient
group that warrants special attention is pregnant women with
diabetes. CGM has proven effective in improving glucose
control at the end of pregnancy [20]. It resulted in fewer
cases of macrosomia in the offspring, with an odds ratio of
0.36 (95% CI 0.13 to 0.98) [21]. As it concerns a limited
time span, reimbursement of CGM in this group should
impose no significant financial burden on the healthcare
system.
Finally, the use of CGM for treating in-hospital hyper-
glycaemia could be valuable, and the first randomised
studies are awaited. However, the advantage of CGM in
this setting may be less evident, as frequent blood sampling
is standard practice in the intensive care unit and CGM
accuracy may suffer if the circulation is compromised [22].
Conclusion
CGM with or without CSII has been proven to lower HbA1c
in adult patients with type 1 diabetes mellitus and HbA1c
values above 8%, when compliant patients who tolerate the
device are selected. However, CGM is not the final answer
to severe hypoglycaemia. Awaiting a cost-effectiveness
analysis, increasing reimbursement of CGM is expected.
Acknowledgements No funding was received for this commentary.
We acknowledge N. Papo (Senior Reimbursement Manager, Medtronic
International Trading Sárl, Tolochenaz Switzerland) for providing
information on the current global reimbursement status of CGM.
Duality of interest J. H. DeVries is a member of the speakers’ bureau
forAbbottDiabetesCareandMedtronicandhisdepartmenthasreceived
research support from these companies. J. Hermanides declares that
there is no duality of interest associated with this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Albisser AM, Leibel BS (1977) The artificial pancreas. Clin
Endocrinol Metab 6:457–479
2. Bolinder J, Ungerstedt U, Arner P (1993) Long-term continuous
glucose monitoring with microdialysis in ambulatory insulin-
dependent diabetic patients. Lancet 342:1080–1085
3. Bolinder J, Ungerstedt U, Arner P (1992) Microdialysis measure-
ment of the absolute glucose concentration in subcutaneous
adipose tissue allowing glucose monitoring in diabetic patients.
Diabetologia 35:1177–1180
4. American Diabetes Association (2008) Standards of medical care
in diabetes—2008. Diabetes Care 31:S12–S54
5. Cryer PE (2008) The barrier of hypoglycemia in diabetes.
Diabetes 57:3169–3176
6. Wentholt IM, Maran A, Masurel N, Heine RJ, Hoekstra JB,
DeVries JH (2007) Nocturnal hypoglycaemia in type 1 diabetic
patients, assessed with continuous glucose monitoring: frequency,
duration and associations. Diabet Med 24:527–532
7. Hanaire H (2006) Continuous glucose monitoring and external
insulin pump: towards a subcutaneous closed loop. Diabetes
Metab 32:534–538
8. Gross TM, Bode BW, Einhorn D et al (2000) Performance
evaluation of the MiniMed continuous glucose monitoring system
during patient home use. Diabetes Technol Ther 2:49–56
9. Deiss D, Bolinder J, Riveline JP et al (2006) Improved glycemic
control in poorly controlled patients with type 1 diabetes using
real-time continuous glucose monitoring. Diabetes Care 29:2730–
2732
10. Hirsch IB, Abelseth J, Bode BW et al (2008) Sensor-augmented
insulin pump therapy: results of the first randomized treat-to-target
study. Diabetes Technol Ther 10:377–383
11. The Juvenile Diabetes Research Foundation Continuous Glucose
Monitoring Study Group (2008) Continuous glucose monitoring
and intensive treatment of type 1 diabetes. N Engl J Med 359:1464–
1476
12. Raccah D, Sulmont V, Reznik Yet al (2009) Incremental value of
continuous glucose monitoring when starting pump therapy in
patients with poorly controlled type 1 diabetes: the RealTrend
study. Diabetes Care 32:2245–2250
13. Hermanides J, Nørgaard K, Bruttomesso D et al (2009) Sensor
augmentedpump therapy substantially lowersHbA1c. Diabetologia
52:S43 (Abstract)
14. Cryer PE (2004) Diverse causes of hypoglycemia-associated
autonomic failure in diabetes. N Engl J Med 350:2272–2279
15. Wentholt IM, Hoekstra JB, DeVries JH (2007) Continuous
glucose monitors: the long-awaited watch dogs? Diabetes Technol
Ther 9:399–409
Diabetologia (2010) 53:593–596 59516. Wentholt IM, Hart AA, Hoekstra JB, DeVries JH (2007)
Relationship between interstitial and blood glucose in type 1
diabetes patients: delay and the push-pull phenomenon revisited.
Diabetes Technol Ther 9:169–175
17. Pham M (2006) Medtronic. Diabetes: Sizing the market for real-
time, continuous blood glucose monitors from MDT, DXCM,
and ABT. Available from www.research.hsbc.com/midas/Res/
RDV?p=pdf&key=ate2b8rygn&name=127057.PDF, accessed 28
September 2009
18. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ (2005) Health-
economic comparison of continuous subcutaneous insulin infusion
with multiple daily injection for the treatment of type 1 diabetes in
the UK. Diabet Med 22:1239–1245
19. Yoo HJ, An HG, Park SYet al (2008) Use of a real time continuous
glucose monitoring system as a motivational device for poorly
controlled type 2 diabetes. Diabetes Res Clin Pract 82:73–79
20. Landon MB, Gabbe SG, Piana R, Mennuti MT, Main EK (1987)
Neonatal morbidity in pregnancy complicated by diabetes mellitus:
predictive value of maternal glycemic profiles. Am J Obstet
Gynecol 156:1089–1095
21. Murphy HR, Rayman G, Lewis K et al (2008) Effectiveness of
continuous glucose monitoring in pregnant women with diabetes:
randomised clinical trial. BMJ 337:a1680
22. Sair MPMF, Etherington PJB, Peter Winlove CD, Evans TWM
(2001) Tissue oxygenation and perfusion in patients with systemic
sepsis. Crit Care Med 29:1343–1349
596 Diabetologia (2010) 53:593–596